Gender differences in patients with COVID-19: Focus on severity and mortality

Jian-Min Jin¹, Peng Bai², Wei He², Fei Wu³, Xiao-Fang Liu², De-Min Han², Shi Liu³, Jin-Kui Yang²*

¹Beijing Tongren Hospita, Capital Medical University, China, ²Beijing Tongren Hospital, Capital Medical University, China, ³Wuhan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, China

Submitted to Journal:
Frontiers in Public Health

Specialty Section:
Infectious Diseases - Surveillance, Prevention and Treatment

Article type:
Original Research Article

Manuscript ID:
545030

Received on:
23 Mar 2020

Revised on:
05 Apr 2020

Frontiers website link:
www.frontiersin.org
Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Author contribution statement

JMJ, PB, FG, WH, SL, FW, DMH SL and JKY collected the epidemiological and clinical data and processed statistical data. JKY drafted the manuscript. JMJ, SL and JKY revised the final manuscript. JKY is responsible for summarizing all epidemiological and clinical data.

Keywords

SARS-CoV-2, COVID-19, SARS, Morbidity, Mortality, gender

Abstract

Word count: 204

Objective: The recent outbreak of Novel Coronavirus Disease (COVID-19) is reminiscent of the SARS outbreak in 2003. We aim to compare the severity and mortality between male and female patients with COVID-19 or SARS.

Study Design and Setting: We extracted the data from (1) a case series of 43 hospitalized patients we treated, (2) a public data set of the first 37 cases died of COVID-19 and 1019 survived patients in China, and (3) data of 524 patients with SARS, including 139 deaths, from Beijing in early 2003.

Results: Older age and high number of comorbidities were associated with higher severity and mortality in patients with both COVID-19 and SARS. Age was comparable between men and women in all data sets. In the case series, however, men tend to be more serious than women (P=0.035). In the public data set, the number of men is 2.4 times that of women in the deceased group (70.3% vs. 29.7%, P=0.016). In SARS patients, the gender role in mortality was also observed. The percentage of male were higher in the deceased group than in the survived group (P=0.015).

Conclusion: Male gender is a risk factor for worse outcomes independent of age and susceptibility in patients with COVID.

Contribution to the field

JMJ, PB, FG, WH, SL, FW, DMH SL and JKY collected the epidemiological and clinical data and processed statistical data. JKY drafted the manuscript. JMJ, SL and JKY revised the final manuscript. JKY is responsible for summarizing all epidemiological and clinical data.

Funding statement

This study was funded by the National Key R&D Program of China (2017YFC0909600).

Ethics statements

Studies involving animal subjects

Generated Statement: No animal studies are presented in this manuscript.

Studies involving human subjects

Generated Statement: The studies involving human participants were reviewed and approved by Ethics Committee of Beijing Tongren Hospital, Capital Medical University. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Inclusion of identifiable human data

Generated Statement: No potentially identifiable human images or data is presented in this study.

Data availability statement
Generated Statement: The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.
Gender differences in patients with COVID-19: Focus on severity and mortality

Jian-Min Jin, MD, PhD\textsuperscript{1,2}, Peng Bai, MD\textsuperscript{1,2}, Wei He, MD\textsuperscript{1,2}, Fei Wu, MD\textsuperscript{2}, Xiao-Fang Liu, MD, PhD\textsuperscript{1}, De-Min Han MD, PhD\textsuperscript{4}, Shi Liu, MD\textsuperscript{2,\*} and Jin-Kui Yang MD, PhD\textsuperscript{5,\*}

\textsuperscript{1}Department of Respiratory and Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
\textsuperscript{2}Department of Internal Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
\textsuperscript{3}Department of Critical Care Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China.
\textsuperscript{4}Department of otolaryngology and head surgery, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. Electronic address: 1455019296@qq.com
\textsuperscript{5}Department of Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China. Electronic address: jkyang@ccmu.edu.cn

\*Address correspondence and reprint requests to
Professor Jin-Kui YANG, Department of Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing 100730, China
Tel: +86-10-58268445
Fax: +86-10-65288736
Cell: +86-13911167636
E-mail: jkyang@ccmu.edu.cn

or
Professor Shi Liu, Department of Internal Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.
Cell: +86-13871162084
E-mail: 1455019296@qq.com

Conflict of Interest: No potential conflicts of interest relevant to this article from all authors were reported.
What is new?

- This is the first preliminary study investigating the gender role in morbidity and mortality in patients with Novel Coronavirus Disease (COVID-19).
- Male gender is a risk factor for worse outcomes and death independent of age in patients with COVID-19.
- While males and females have the same prevalence of COVID-19, male patients have a higher mortality.
Abstract

Objective: The recent outbreak of Novel Coronavirus Disease (COVID-19) is reminiscent of the SARS outbreak in 2003. We aim to compare the severity and mortality between male and female patients with COVID-19 or SARS.

Study Design and Setting: We extracted the data from (1) a case series of 43 hospitalized patients we treated, (2) a public data set of the first 37 cases died of COVID-19 and 1019 survived patients in China, and (3) data of 524 patients with SARS, including 139 deaths, from Beijing in early 2003.

Results: Older age and high number of comorbidities were associated with higher severity and mortality in patients with both COVID-19 and SARS. Age was comparable between men and women in all data sets. In the case series, however, men tend to be more serious than women (P=0.035). In the public data set, the number of men is 2.4 times that of women in the deceased group (70.3% vs. 29.7%, P=0.016). In SARS patients, the gender role in mortality was also observed. The percentage of male were higher in the deceased group than in the survived group (P=0.015).

Conclusion: Male gender is a risk factor for worse outcomes independent of age and susceptibility in patients with COVID.

Keywords: SARS-CoV-2; COVID-19; SARS; morbidity; mortality
1. Introduction

In early December 2019, an outbreak of a novel coronavirus disease (COVID-19) in Wuhan city and the rapidly spread throughout China has put the world on alert. High-throughput sequencing has revealed a novel β-coronavirus that is currently named as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1], which resembled severe acute respiratory syndrome coronavirus (SARS-CoV)[2]. Most patients with COVID-19 were Mild. Moderate patients often experienced dyspnea after one week. Severe patients progressed rapidly to Critical conditions including acute respiratory distress syndrome (ARDS), acute respiratory failure, coagulopathy, septic shock, and metabolic acidosis.

Early identification of risk factors for Critical conditions is urgently warranted not only to identify the defining clinical and epidemiological characteristics with greater precision, but also facilitated appropriate supportive care and promptly access to the intensive care unit (ICU) if necessary.

The Chinese health authority has announced that the total number of confirmed cases on the Chinese mainland has reached 76,936, and 2,442 people have died of the disease as of Feb 23. Among the 2,442 deceased patients, most were old and two-thirds were males, though the detailed data has not been reported[3]. This raises a question: Are men more susceptible to getting and dying from COVID-19?

Here, we reported the clinical characteristics of a recent case series of 43 patients we treated, a public data set of the first 37 cases died and the 1019 survived patients with COVID-19. We aimed to compare the severity and mortality in male and female patients with COVID-19, to explore the most useful prognostic factor for individualized assessment. SARS-CoV-2 infection is reminiscent of the SARS-CoV outbreak in early 2003, because both viruses attack cells via the same ACE2 receptor[3]. In this study,
we also analyzed the data of 524 SARS patients, including 139 deaths, from Beijing in early 2003.

2. Materials and methods

2.1 Patients and data sources

Cases series of COVID-19: In the case series analysis, a recent case series of 43 patients with COVID-19 was treated at Wuhan Union Hospital by the medical team of Beijing Tongren Hospital from January 29, 2020 to February 15, 2020.

Public data set of COVID-19: the first 37 cases died and 1019-cases of COVID-19 survivors from the public data set from the Chinese Public Health Science Data Center.

Cases series of SARS: This study also included data of 524 SARS patients including 139 deaths from 29 hospitals, in early 2003. These patients were hospitalized in Beijing between 25 March and 22 May 2003.

Diagnosis and clinical classification criteria and treatment plan (trial version 5) of COVID-19 was launched by the National Health Committee of the People's Republic of China (http://www.nhc.gov.cn/). The clinical classification of severity is as follows: (1) Mild, only mild symptoms, imaging shows no pneumonia. (2) Moderate, with fever, respiratory tract symptoms, and imaging shows pneumonia. (3) Severe, meet any of the following signs: a) respiratory distress, respiratory rate ≥ 30 beats / min; b) in the resting state, finger oxygen saturation ≤ 93%) arterial blood oxygen partial pressure (PaO2/oxygen concentration (FiO2) ≤ 300mmHg (1mmHg = 0.133kPa). (4) Critical, one of the following conditions: a) respiratory failure occurs and requires mechanical ventilation; b) Shock occurs; c) ICU admission is required for combined organ failure.

The study protocol was approved by the Ethics Committee of Beijing Tongren Hospital, Capital Medical University.

2.2 Statistical analysis
Data were expressed as mean ± SD, median (interquartile range (IQR)) or percentage, as appropriate. Compared the differences between the two groups, mean values and percentages were compared between the two groups by the Student \( t \)-test, Mann-Whitney U test or chi-square (\( \chi^2 \)) test. Kaplan–Meier survival curves and the log-rank test was used for testing the survival between males and females. Statistical analyses were performed using the SAS software (version 9.4). \( P< 0.05 \) (two-tailed) was considered to be statistically significant.

3. Results

3.1 Case series of COVID-19

The demographic and clinical characteristics are shown in Table 1. The median age was 62 years (IQR, 51 to 70). Fever (95.3%) and cough (65.1%) were the most common symptoms, while diarrhea (16.3) was not common. 37.2% of patients had at least one underlying disorder (i.e., hypertension, diabetes, cardiovascular diseases and chronic lung diseases). There is no significant difference in median age between male and female groups, but the maximum of the range of IQR is lower in male (66 years in men vs. 73 years in women). Symptoms and comorbidities were comparable between men and women. As expected, men had a higher level of hemoglobin. However, male patients also had elevated serum creatinine, white blood cells and neutrophils. Among the 43-case series, 13 (30.2%) were diagnosed with \textit{Mild or Moderate} pneumonia, 14 (32.6%) and 16 (37.2%) were diagnosed with \textit{Severe} and \textit{Critical} pneumonia, respectively. Chi-square (\( \chi^2 \)) test for trend indicated that men tend to be more serious than women (\( P=0.035 \)) according to the clinical classification of severity (Figure 1).

3.2 Public data set of COVID-19

In the deceased patients, fever (86.5%) and cough (67.6%) were common, while diarrhea was uncommon (18.9%), 64.9% had at least one underlying disorder (i.e.,
hypertension, diabetes, cardiovascular disease, or chronic obstructive pulmonary disease). The median period from symptom onset to death was 13 days (ranging from 11 to 18 days). Of these deceased patients, (Table 2).

The deceased patients were significantly older (median (IQR), 70.3 (65-81) years) and had a higher percentage of ≥65 years (83.8%), in comparison to those who survived (47 (35-57) years old and 13.2% ≥65 years). COVID-19 was diagnosed throughout the whole spectrum of age. There were 30 (2.9%) pediatric patients (<14 years) in the survived group. None of the 37 deceased cases was pediatric patient (Table 2 and Figure 2A). Ages were comparable between men and women in both deceased and survived patients (Figure 2B). Of the 37 deceased patients, 70.3% were men, 29.7% were woman. the number of men is 2.4 times that of women in the deceased patients. While men and women had the same susceptibility, men were more prone to dying ($\chi^2$ test, $P=0.016$) (Figure 2C).

3.3 Cases series of SARS, in 2003

Between March 25 and May 22, 2003, a total of 524 SARS patients including 139 deaths in Beijing area reported from 29 hospitals were enrolled in our analysis. Fever (98.4%) and cough (76.9%) were the most common symptoms, while diarrhea (6.7%) was not common. 57.0% of the patients had at least one of the concomitant diseases including hypertension, diabetes, cardiovascular diseases and chronic lung diseases. The mean duration from self-reported symptom to death was 15 (IQR: 10-19) days. Table 2 summarizes the clinical and biochemical characteristics of all SARS patients. The median age of the deceased patients was much higher than that of the survived patients (57 vs. 32, $P<0.001$). The rate of the concomitant diseases in the deceased patients was also higher than that of the survived patients (57.0% vs. 17.9%, $P<0.001$). While the deceased patients were significantly older than the survived patients (Figure
3A), ages were comparable between men and women in both deceased and survived patients with SARS (Figure 3B). The proportion of male gender was higher in the deceased group (53.2%) than in the survived group (42.3%) ($\chi^2$ test, \(P=0.027\)) (Figure 3C). Survival analysis showed that men had a significantly higher mortality rate than women (31.2% vs. 22.6%) in this hospital-based cohort (hazard ratio [95% CI] 1.47 [1.05-2.06], \(P=0.026\)) (Figure 3D).

4. Discussion

Coronavirus is a large family of viruses that cause illness ranging from the common cold to severe pneumonia such as SARS[2] and Middle East Respiratory Syndrome (MERS)[4]. SARS-CoV-2 was first identified in Wuhan city, China by the Chinese Center for Disease Control and Prevention (CDC)[5]. Both epidemiological[6, 7] and clinical[8, 9] features of patients with COVID-19 have recently been reported. However, few data on prognostic factors of COVID-19 have been reported.

In Case series of COVID-19, consistent with previous reports[9-11], older patients (≥65 years old), were more likely to have a Severe type of COVID-19. Men tend to be more serious than women according to the clinical classification of severity. In Public data set of COVID-19, we also found that the percentage of older age (≥65 years) was much higher in the deceased patient than in the survived patients (83.8% in 37 deceased patients vs. 13.2% in 1019 survived patients).

The number of men is 2.4 times that of women in the deceased patients. While men and women had the same susceptibility, men were more prone to dying.

This is the first preliminary study investigating the gender role in morbidity and mortality of SARS-CoV-2 infection. One study in 425 patients with COVID-19 indicated that 56% were males [6]. Another study in 140 patients found that 50.7% were males [10]. In the present study, similar susceptible to SARS-CoV-2 between males and
females was observed in 1019 survived patients (50.0% males) collected from public
data set and in a case series of 43 hospitalized patient (51.2% males). Although the
deceased patients were significantly older than the survived patients with COVID-19,
ages were comparable between males and females in both the deceased and the survived
patients. Therefore, Gender is a risk factor for higher severity and mortality in patients
with COVID-19 independent of age and susceptibility. This gender factor, as well as
higher incidence in men for most of the diseases, could correlate with a general
demographic fact of a shorter life expectancy in men compared to women in China and
in general in the world. Although there is no significant difference in median age
between male and female groups, the maximum of the range of IQR is lower in male in
the case series.

In early 2003, we participated in the Beijing Municipal Medical Taskforce of
SARS[12]. Here, we re-analyzed the data of a large population of 520 SARS patients
including 135 deaths in Beijing, and summarized the experience and lessons for present
use, because SARS-CoV-2 and SARS-CoV attack cells via the same receptor, ACE2[3].
We have previously reported that high protein expression of ACE2 receptor in specific
organs correlated with specific organ failures indicated by corresponding clinical
parameters in SARS patients[12, 13]. It has been shown that circulating ACE2 levels
are higher in men than in women and in patients with diabetes or cardiovascular
diseases[14].

This study has some limitations. First, for severity analysis only a case series of 43
patients with SARS-CoV-2 were included, because detailed patient information,
particularly regarding clinical outcomes was unavailable in the public data set; Second,
for mortality analysis only the first 37 cases died of SARS-CoV-2 were included. Due
to the urgent circumstances we are living, there was no access with enough time for a
unique, homogeneous data for COVID. It could affect the analysis and any possible bias results. However, this is the first preliminary data investigating the gender role in morbidity and mortality in patients with SARS-CoV-2. More clinical and basic research regarding gender and other prognostic factors for individualized assessment and treatment is needed in the future.

In conclusion, this is the first preliminary study investigating the gender role in morbidity and mortality in patients with COVID-19. Male gender is a risk factor for worse outcomes and death independent of age and susceptibility.

Acknowledgments
This study was funded by the National Key R&D Program of China (2017YFC0909600). We thank all patients involved in the study, High-level Talent Training Foundation of Beijing Health System (2014–3-011), and Beijing Talent Training Foundation (No 2009D003003000002).

This manuscript has been released as a pre-print at https://www.medrxiv.org/content/10.1101/2020.02.23.20026864v2. (Jin et al.)[15]

Author Contributions
JM, PB, FG, WH, SL, FW, DMH SL and JKY collected the epidemiological and clinical data and processed statistical data. JKY drafted the manuscript. JMJ, SL and JKY revised the final manuscript. JKY is responsible for summarizing all epidemiological and clinical data.

References


Table 1. Characteristics of a *Case series of COVID-19*.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Total (n=43)</th>
<th>Male (n=22)</th>
<th>Female (n=21)</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age, median (range) – year</strong></td>
<td>62 (51-70)</td>
<td>59 (51-66)</td>
<td>63 (52-73)</td>
<td>0.734</td>
</tr>
<tr>
<td><strong>Symptoms</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever – n (%)</td>
<td>41 (95.3)</td>
<td>21 (95.5)</td>
<td>20 (95.2)</td>
<td>0.490</td>
</tr>
<tr>
<td>Diarrhea – n (%)</td>
<td>7 (16.3)</td>
<td>3 (13.6)</td>
<td>4 (19.0)</td>
<td>0.946</td>
</tr>
<tr>
<td>Cough – n (%)</td>
<td>28 (65.1)</td>
<td>16 (72.7)</td>
<td>12 (57.1)</td>
<td>0.452</td>
</tr>
<tr>
<td><strong>Comorbidities</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension – n (%)</td>
<td>10 (23.3)</td>
<td>6 (27.3)</td>
<td>4 (19.0)</td>
<td>0.782</td>
</tr>
<tr>
<td>Diabetes history – n (%)</td>
<td>5 (11.6)</td>
<td>4 (18.2)</td>
<td>1 (0.5)</td>
<td>0.370</td>
</tr>
<tr>
<td>Cardiovascular diseases – n (%)</td>
<td>4 (9.3)</td>
<td>2 (9.1)</td>
<td>2 (10.0)</td>
<td>0.634</td>
</tr>
<tr>
<td>Chronic lung diseases – n (%)</td>
<td>1 (0.2)</td>
<td>1 (0.5)</td>
<td>0 (0)</td>
<td>0.981</td>
</tr>
<tr>
<td>From symptom to diagnosis, median (range) – day</td>
<td>12 (8-14)</td>
<td>12 (7-13)</td>
<td>12 (10-14)</td>
<td>0.250</td>
</tr>
<tr>
<td>Aspartate aminotransferase – IU/l</td>
<td>42.4±18.9</td>
<td>43.0±15.3</td>
<td>41.7±22.6</td>
<td>0.872</td>
</tr>
<tr>
<td>Alanine aminotransferase – IU/l</td>
<td>42.8±19.0</td>
<td>45.0±18.0</td>
<td>40.4±19.5</td>
<td>0.590</td>
</tr>
<tr>
<td>Alkaline phosphatase – IU/l</td>
<td>53.4±10.6</td>
<td>52.6±11.9</td>
<td>54.3±9.0</td>
<td>0.736</td>
</tr>
<tr>
<td>Lactate dehydrogenase – IU/l</td>
<td>369.4±132.7</td>
<td>414.8±136.2</td>
<td>321.8±112.9</td>
<td>0.064</td>
</tr>
<tr>
<td>Serum creatinine – μmol/l</td>
<td>75.3±21.1</td>
<td>90.4±22.2</td>
<td>59.4±10.9</td>
<td>0.000</td>
</tr>
<tr>
<td>Fasting Blood Glucose – mmol/l</td>
<td>7.3±1.8</td>
<td>7.7±2.0</td>
<td>6.7±1.5</td>
<td>0.325</td>
</tr>
<tr>
<td>High sensitive C-reactive protein – mg/l</td>
<td>52.3±27.8</td>
<td>58.9±29.2</td>
<td>45.6±25.3</td>
<td>0.323</td>
</tr>
<tr>
<td>White blood cells – ×10^9/l</td>
<td>6.8±2.2</td>
<td>7.7±2.3</td>
<td>5.8±1.5</td>
<td>0.027</td>
</tr>
<tr>
<td>Hemoglobin – g/l</td>
<td>128.8±13.6</td>
<td>139.0±11.2</td>
<td>117.6±8.6</td>
<td>0.000</td>
</tr>
<tr>
<td>Platelets – ×10^9/l</td>
<td>225.2±57.4</td>
<td>230.4±54.1</td>
<td>219.6±60.0</td>
<td>0.682</td>
</tr>
<tr>
<td>Neutrophils – ×10^9/l</td>
<td>5.4±2.2</td>
<td>6.4±2.4</td>
<td>4.3±1.3</td>
<td>0.019</td>
</tr>
<tr>
<td>Lymphocytes – ×10^9/l</td>
<td>1.0±0.4</td>
<td>0.9±0.3</td>
<td>1.1±0.4</td>
<td>0.284</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SD, medians (interquartile ranges, IQR) and no. (%).
Table 2. Characteristics of a Public data set of COVID-19 and a Cases series of SARS, in 2003

<table>
<thead>
<tr>
<th></th>
<th>COVID-19</th>
<th>SARS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Deceased (n=37)</td>
<td>Survived (n=1019)</td>
</tr>
<tr>
<td>Age, median (range) – year</td>
<td>70 (65-81) **</td>
<td>47 (35-57)</td>
</tr>
<tr>
<td>Male – n (%)</td>
<td>26 (70.3)*</td>
<td>510 (50.0)</td>
</tr>
<tr>
<td>Symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fever – %</td>
<td>32 (86.5)</td>
<td>136 (97.8)</td>
</tr>
<tr>
<td>Diarrhea – %</td>
<td>7 (18.9)</td>
<td>30 (21.6)</td>
</tr>
<tr>
<td>Cough – %</td>
<td>25 (67.6)</td>
<td>107 (77.0)</td>
</tr>
<tr>
<td>Comorbidities – %</td>
<td>24 (64.9)</td>
<td>79 (56.8) ††</td>
</tr>
<tr>
<td>Hypertension – %</td>
<td>18 (48.6)</td>
<td>64 (46.0) ††</td>
</tr>
<tr>
<td>Diabetes history – %</td>
<td>11 (29.7)</td>
<td>30 (21.6) ††</td>
</tr>
<tr>
<td>Cardiovascular disease – %</td>
<td>8 (21.6)</td>
<td>40 (28.8) ††</td>
</tr>
<tr>
<td>Chronic lung disease – %</td>
<td>3 (8.1)</td>
<td>5 (3.6)</td>
</tr>
<tr>
<td>From onset to death, median (range) – day</td>
<td>13 (11-18)</td>
<td>15 (10-19)</td>
</tr>
</tbody>
</table>

Data are presented as medians (interquartile ranges, IQR) and n (%).

* p<0.05, ** p<0.01, vs. COVID-19 survived patients.
† p<0.05, †† p<0.01, vs. SARS survived patients.
Figure legend

Figure 1 Trend data of clinical classification of severity in a Case series of COVID-19.

Numbers of cases of men or women in different clinical classes of severity. Chi-square ($\chi^2$) test for trend indicated that males tend to be more serious than females according to the clinical classification of severity including Mild+Moderate, Severe and Critical.

Figure 2 Role of age and gender in morbidity and mortality in a Public data set of COVID-19.

(A) The whole spectrum of age in deceased and survived patients with COVID.

(B) Comparation of age between males and females in both deceased and survived patients with COVID.

(C) Gender distribution in both deceased and survived patients with COVID.

Figure 3 Role of age and gender in morbidity and mortality in a Cases series of SARS, in 2003.

(A) The whole spectrum of age in deceased and survived patients with SARS.

(B) Comparation of age between males and females in both deceased and survived patients with SARS.

(C) Gender distribution in both deceased and survived patients with SARS.

(D) Survival analysis comparing mortality rates between male and female patients with SARS.
Figure 1

χ² test for trend
χ² = 4.45
P = 0.0349

Patients (n)

Mild+Moderate  Severe  Serious

Male  Female
Figure 2

A

Died (n=37) Survived (n=1019)

- ≥65
- 50<65
- 14<50
- 0<14

χ² test for trend
χ² = 89.6
P<0.0001

B

Died Survived

Age (year)

Male Female Male Female

C

Died (n=37) Survived (n=1019)

- Male
- Female

χ² test
χ² = 5.84
P=0.0157
Figure 3

A

Died (n=139) Survived (n=385)

$\chi^2$ test for trend
$\chi^2 = 143.1$
P<0.0001

B

Age (year)

Died Survived

Male Female Male Female

C

Died (n=139) Survived (n=385)

$\chi^2$ test
$\chi^2 = 4.898$
P=0.0269

D

Percent survival

Days elapsed

Male Female

P = 0.0255

Patients at risk

Male 237 223 193 177 170 169 167 166 164
Female 287 274 251 236 229 224 224 222